Short term effects of letrozole [Femara] on bone markers and vascular indices in postmenopausal women after completion of tamoxifen therapy for primary breast cancer

Trial Profile

Short term effects of letrozole [Femara] on bone markers and vascular indices in postmenopausal women after completion of tamoxifen therapy for primary breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2010

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer; Osteoporosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 09 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top